ScoreWhy is Prelude Therapeutics, Inc. ?
1
With a growth in Net Sales of INF%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- NET SALES(HY) At USD 10.22 MM has Grown at 155.5%
- OPERATING CASH FLOW(Y) Highest at USD -43.75 MM
- OPERATING PROFIT(Q) Highest at USD -13.79 MM
2
High Institutional Holdings at 52.49%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
3
Market Beating Performance
- The stock has generated a return of 409.30% in the last 1 year, much higher than market (S&P 500) returns of 19.75%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Prelude Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Prelude Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Prelude Therapeutics, Inc.
409.3%
0.05
204.66%
S&P 500
19.75%
1.50
13.19%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
67.39%
EBIT Growth (5y)
-26.10%
EBIT to Interest (avg)
-118.58
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.49%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.80
EV to EBIT
-0.88
EV to EBITDA
-0.89
EV to Capital Employed
-2.88
EV to Sales
7.55
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-144.96%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
NET SALES(HY)
At USD 10.22 MM has Grown at 155.5%
OPERATING CASH FLOW(Y)
Highest at USD -43.75 MM
OPERATING PROFIT(Q)
Highest at USD -13.79 MM
PRE-TAX PROFIT(Q)
Highest at USD -10.38 MM
NET PROFIT(Q)
Highest at USD -10.38 MM
RAW MATERIAL COST(Y)
Fallen by -9,146% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -106.06 %
EPS(Q)
Highest at USD -0.13
-1What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 184.77 MM
Here's what is working for Prelude Therapeutics, Inc.
Net Sales
At USD 10.22 MM has Grown at 155.5%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -43.75 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -13.79 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -10.38 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -10.38 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Pre-Tax Profit
At USD -10.38 MM has Grown at 67.63%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
At USD -10.38 MM has Grown at 67.63%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.13
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Debt-Equity Ratio
Lowest at -106.06 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -9,146% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Prelude Therapeutics, Inc.
Cash and Eqv
Lowest at USD 184.77 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
